Cleveland v. Ludwig Institute for Cancer Research Ltd

District Court, S.D. California·Decided October 27, 2021·No. 3:19-cv-02141·Unknown

Opinion

1 2 3 4 5 6 7 8 UNITED STATES DISTRICT COURT 9 SOUTHERN DISTRICT OF CALIFORNIA 10 11 DON CLEVELAND, et al., Case No.: 19-cv-02141-JM (JLB)

12 Plaintiffs, [REDACTED] ORDER GRANTING 13 v. IN PART AND DENYING IN PART DEFENDANTS/ COUNTER- 14 LUDWIG INSTITUTE FOR CANCER CLAIMANTS’ MOTION FOR RESEARCH LTD., et al., 15 SANCTIONS FOR PLAINTIFFS’ Defendants. VIOLATION OF THIS COURT’S 16 PROTECTIVE ORDER 17 [ECF No. 80] 18

19 Before the Court is a motion for sanctions filed by Defendants/Counter-Claimants 20 Ludwig Institute for Cancer Research Ltd. (“Ludwig”), Chi Van Dang, Edward A. 21 McDermott, Jr., and John L. Notter (collectively, “Defendants”). (ECF No. 80.) 22 Defendants move for an order sanctioning Plaintiffs/Counter-Defendants Don Cleveland, 23 Arshad Desai, Frank Furnari, Richard Kolodner (“Kolodner”), Paul Mischel, 24 Karen Oegema, and Bing Ren (collectively, “Plaintiffs”) for violations of the Protective 25 Order issued in this case. (Id. at 2.) Plaintiffs filed an opposition. (ECF No. 83.) 26 Defendants filed a reply. (ECF No. 85.) For the reasons set forth below, the Court 27 GRANTS IN PART and DENIES IN PART Defendants’ motion for sanctions. 28 /// 1 I. BACKGROUND 2 A. Ludwig I 3 On November 7, 2019, Plaintiffs commenced the above-captioned action, 4 Cleveland, et al. v. Ludwig Institute for Cancer Research Ltd, et al., Case No. 19-cv-02141- 5 JM-JLB (S.D. Cal.) (“Ludwig I”). (ECF No. 1.) On July 8, 2020, Plaintiffs filed a Second 6 Amended Complaint (“SAC”), the operative complaint. (ECF No. 26.) 7 According to the SAC, Plaintiffs are internationally acclaimed cancer research 8 scientists and physicians. (SAC ¶ 1.) Ludwig is an international nonprofit organization 9 dedicated to finding a cure for cancer that operates multiple cancer research branches. (Id. 10 ¶¶ 1, 142.) In 1991, Ludwig entered into an “Affiliation Agreement” (“the AA”) with the 11 University of California at San Diego (“UCSD”) to establish a San Diego Branch (“the 12 Branch”). (Id. ¶ 51.) Ludwig agreed to conduct “active” and “continuous” medical 13 research to “discover, develop, or verify knowledge related to causes, diagnoses, treatment, 14 prevention and control of cancer.” (Id. ¶ 53.) Ludwig also agreed to “bear the costs directly 15 related to conducting the research program.” (Id. ¶ 62.) The term of the AA is coterminous 16 with a lease agreement for research facilities between Ludwig and UCSD, which allows 17 Ludwig to terminate the lease no earlier than December 31, 2023. (Id. ¶¶ 4, 16, 56.) In 18 addition to leasing its facilities to Ludwig, UCSD agreed to: (1) grant privileges for the 19 practice of medicine at its hospital to qualified members of the medical staff at the Branch; 20 (2) grant “academic recognition and titles” to qualified Ludwig employees; and (3) make 21 full time equivalency positions available for Ludwig employees. (Id. ¶ 154.) 22 Between 1996 and 2016, Ludwig hired Plaintiffs to work at the Branch. (Id. ¶¶ 26– 23 32.) In 2018, Ludwig announced that it would “cease funding the Branch and otherwise 24 halt the ‘continuous active conduct of medical research’ at the Branch.” (Id. ¶ 15.) 25 Effective January 1, 2020, Ludwig “terminated all funding for Plaintiffs’ laboratories.” (Id. 26 ¶ 18.) However, “Ludwig continues to fund at least part of the rent due [to UCSD] and it 27 continues to pay the Plaintiffs’ own salaries and benefits, but nothing more.” (Id.) As a 28 result, Plaintiffs’ “[l]aboratories and ongoing translational research programs have ceased 1 or substantially curtailed ongoing research projects, except to the extent that they have 2 access to outside grants.” (Id.) 3 In their SAC, Plaintiffs asserted the following claims against Ludwig: (1) breach of 4 the AA; (2) breach of Plaintiffs’ Intellectual Property (“IP”) agreements; (3) breach of 5 Plaintiffs’ lab contracts; (4) breach of the implied covenant of good faith and fair dealing; 6 (5) promissory estoppel under the AA; (5) declaratory relief; and (6) false light. (SAC ¶¶ 7 145–70, 182–303.) Plaintiffs also bring a claim against all Defendants for defamation per 8 se. (Id. ¶¶ 171–81.) On November 25, 2020, the Honorable Jeffrey T. Miller dismissed 9 Plaintiffs’ claims for breach of the AA and breach of Plaintiffs’ IP agreements. (ECF No. 10 32 at 28.) He also dismissed Plaintiffs’ declaratory relief claim with respect to Plaintiffs’ 11 claims based on the AA and IP agreements, and their claim for breach of the implied 12 covenant in the AA and lab contracts. (Id.) 13 B. Ludwig II 14 On May 5, 2021, Plaintiffs filed a separate lawsuit against Ludwig: Cleveland, et al. 15 v. Ludwig Institute for Cancer Research Ltd., Case No. 21-cv-00871-JM-JLB (S.D. Cal.) 16 (“Ludwig II”). (Ludwig II, ECF No. 1.) In Ludwig II, Plaintiffs bring claims against 17 Ludwig for: (1) retaliation in violation of California Government Code § 12940(h); (2) age 18 discrimination under the Fair Employment and Housing Act (“FEHA”); (3) wrongful 19 adverse employment action in violation of public policy; (4) failure to timely pay wages; 20 and (5) violation of California’s unfair competition laws. (Id. at 13–21.) Kolodner also 21 brings a separate claim for retaliation in violation of California Labor Code § 1102.5. (Id. 22 at 12–13.) 23 On May 12, 2021, Ludwig II was low number transferred to Judge Miller and the 24 undersigned judge for all further proceedings. (ECF No. 4.) On July 2, 2021, Judge Miller 25 denied Plaintiffs’ motion to consolidate Ludwig I and Ludwig II. (ECF No. 13.) On July 26 6, 2021, Ludwig filed a motion to dismiss all claims in the Ludwig II complaint pursuant 27 to Federal Rule of Civil Procedure 12(b)(6). (ECF No. 14.) No answer has been filed. 28 /// 1 C. Protective Order 2 On February 19, 2021, the parties filed a joint motion for entry of stipulated 3 protective order in Ludwig I. (ECF No. 44.) The proposed protective order was largely 4 based on the Southern District of California’s model protective order, which is available 5 on the district court’s website. The proposed protective order also contained the 6 undersigned judge’s required language, as set forth in her Civil Chambers Rules. See J. 7 Burkhardt Civ. Chambers R. § VI.B. On February 22, 2021, the Court granted the joint 8 motion and entered the parties’ stipulated protective order (“Protective Order”). (ECF No. 9 45.) 10 The Protective Order was entered for the purpose of protecting the confidentiality of 11 documents and information that are, for competitive reasons, normally kept confidential 12 by the parties. (Id. at 1.) These materials “may contain trade secret or other confidential 13 research, technical, cost, price, marketing or other commercial information, as is 14 contemplated by Federal Rule of Civil Procedure 26(c)(1)(G).” (Id. at 2.) To serve this 15 purpose, the Protective Order permits each party to the litigation to designate materials as 16 “CONFIDENTIAL” or “CONFIDENTIAL—FOR COUNSEL ONLY.” (Id. ¶ 4.) The 17 Protective Order permits the designations as follows: 18 a. Designation as “CONFIDENTIAL”: Any party or non-party subject to 19 this Order may designate documents or other information in this action as “CONFIDENTIAL” only if the designating party or non-party and 20 their counsel has an articulable, good faith basis to believe that each 21 document or other information designated as “CONFIDENTIAL” qualifies for protection under Federal Rule of Civil Procedure 26(c). 22 b.

Free access — add to your briefcase to read the full text and ask questions with AI

Cleveland v. Ludwig Institute for Cancer Research Ltd, (S.D. Cal. 2021).

Cleveland v. Ludwig Institute for Cancer Research Ltd (Cleveland v. Ludwig Institute for Cancer Research Ltd) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Chambers v. Nasco, Inc.
501 U.S. 32 (Supreme Court, 1991)
United States v. Alfred Glass
720 F.2d 21 (Eighth Circuit, 1983)
R & R Sails, Inc. v. Insurance Co. of Pennsylvania
673 F.3d 1240 (Ninth Circuit, 2012)
Marine Midland Realty Credit Corp. v. LLMD of Michigan, Inc.
821 F. Supp. 370 (E.D. Pennsylvania, 1993)
On Command Video Corp. v. LodgeNet Entertainment Corp.
976 F. Supp. 917 (N.D. California, 1997)
Kashani v. TSANN KUEN CHINA ENTERPRISE CO.
13 Cal. Rptr. 3d 174 (California Court of Appeal, 2004)
Gomez v. Vernon
255 F.3d 1118 (Ninth Circuit, 2001)
In re Vitamins Antitrust Litigation
211 F.R.D. 1 (District of Columbia, 2002)
Pacific Lumber Co. v. National Union Fire Insurance
220 F.R.D. 349 (N.D. California, 2003)
CBS Interactive, Inc. v. Etilize, Inc.
257 F.R.D. 195 (N.D. California, 2009)
Stein v. Board of City of New York
792 F.2d 13 (Second Circuit, 1986)